Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuning Le

Showing results (161-170 of 179) with videos related to

Pageof 18
Sort By:
Research Square|May 27, 2024
The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasionXin Hu, Bo Zhu, Natalie Vokes, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic TargetXiuning Le, Marcelo V Negrao, Alexandre Reuben, et al.
Nature Communications|April 11, 2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insightsSheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
The New England Journal of Medicine|May 30, 2020
Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K Paik, Enriqueta Felip, Remi Veillon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.
Nature Medicine|May 29, 2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistanceYanshuo Chu, Enyu Dai, Yating Li, et al.
Pageof 18

Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Research Square|May 27, 2024
The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasionXin Hu, Bo Zhu, Natalie Vokes, et al.
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic TargetXiuning Le, Marcelo V Negrao, Alexandre Reuben, et al.
Nature Communications|April 11, 2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insightsSheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
The New England Journal of Medicine|May 30, 2020
Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K Paik, Enriqueta Felip, Remi Veillon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.
Nature Medicine|May 29, 2023
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistanceYanshuo Chu, Enyu Dai, Yating Li, et al.
Pageof 18